Oncology
Cancer therapy continues to be a key innovation area for us. We are interested in newly identified cancer targets, antibodies, and other novel approaches to provided enhance immuno-oncology treatment.
Microbiome
Dysregulation of the microbiome can lead to a broad range of diseases. We are interested in functionally directed natural microbiome strains and mechanistically defined molecules that we can exploit through oral-based drugs and biotherapy products.
Longevity
We seek groundbreaking innovations that significantly enhance overall physiological well-being by extending lifespan and extending human performance across neurological function, immune response, physical mechanics, metabolic efficiency, and cellular regeneration.
Autoimmunity
Targeted approaches to induce tolerance to re-stablished immune system homoeostasis is a key innovation area for us. These include various modalities, platforms and administration routes.
Inflammation
We are interested in novel targets that will lead to products that can prevent or reduce inflammation, especially for lung and skin fibrosis, liver, and neurological inflammation
Infectious Disease
New vaccines and therapeutic approaches to prevent infectious disease. We are especially interested in new delivery approaches and adjuvants to strengthen and fight against existing pathogens and prevent future pandemics.